IONS – ionis pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal [Yahoo! Finance]
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at JPMorgan Chase & Co. from $51.00 to $47.00. They now have a "neutral" rating on the stock.
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
Ionis to present at upcoming investor conferences [Yahoo! Finance]
Form 8-K IONIS PHARMACEUTICALS For: Mar 11
Form 144 IONIS PHARMACEUTICALS Filed by: Monia Brett P
Form 4 IONIS PHARMACEUTICALS For: Feb 28 Filed by: Swayze Eric
Form 4 IONIS PHARMACEUTICALS For: Feb 28 Filed by: Monia Brett P
Form 4 IONIS PHARMACEUTICALS For: Feb 28 Filed by: Geary Richard S
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.